<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04173338</url>
  </required_header>
  <id_info>
    <org_study_id>IST-65</org_study_id>
    <nct_id>NCT04173338</nct_id>
  </id_info>
  <brief_title>Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma</brief_title>
  <official_title>Phase I Study of Cabozantinib in Combination With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC), Urothelial Cancer and Advanced Malignant Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will combine cabozantinib with pemetrexed to treat patients with non-small cell
      lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the
      safety of both drugs used together and see what effect (good or bad) it has no participants
      and their cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the maximum tolerated dose (MTD) of cabozantinib in combination with pemetrexed</measure>
    <time_frame>4 weeks or 28 days assessment.</time_frame>
    <description>Dose-limiting toxicity of grade 3 or higher using CTCAE 5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess objective response rate (RR)</measure>
    <time_frame>To be measured through study completion; an average of 1 year.</time_frame>
    <description>RR measured by Tumor response evaluation with RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>To be measured through study completion; an average of 1 year.</time_frame>
    <description>PFS measured from the time of study treatment to the date of progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS).</measure>
    <time_frame>OS measured through study completion, and an average of 1 year</time_frame>
    <description>Measured from the time of start of treatment to time of death or time of last assessment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Non-squamous Non-small-cell Lung Cancer</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Malignant Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Cabozantinib + Pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pemetrexed 500mg/m2 IV day 1 of each 21 day cycle + Cabozantinib 20-60mg by mouth once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>start at 20mg then increase by 20mg every cycle or until there's a dose-limiting toxicity.</description>
    <arm_group_label>Cabozantinib + Pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Start with 400mg/m2, then increase and maintain 500mg/m2 unless dose-limiting toxicity.</description>
    <arm_group_label>Cabozantinib + Pemetrexed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally advanced NSCLC, urothelial cancer or malignant mesothelioma.

          -  18 years or older.

          -  At least one prior chemotherapy before entering in this trial.

          -  Not pregnant or breastfeeding.

        Exclusion Criteria:

          -  Prior treatment with cabozantinib.

          -  Currently receiving cancer treatment (last dose 2 weeks prior to enrollment in study).

          -  History of bleeding disorder/bleeding history within 12 weeks before first study
             treatment dose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagla A Karim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University Georgia Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelly Jenkins, MSN, RN</last_name>
    <phone>706-721-1206</phone>
    <email>kejenkins@augusta.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashlyn Stevenson, BSN, RN</last_name>
    <phone>706-721-0660</phone>
    <email>asstevenson@augusta.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Augusta University Georgia Cancer Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nagla A Karim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Nagla Abdel Karim</investigator_full_name>
    <investigator_title>Professor, Hematology/Oncology, Director of Thoracic Oncology and Phase I Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

